nuButyrate™

Helping support digestive and gastrointestinal health through impacting gene expression, Tributyrin is the only form to be clinically substantiated bioavailability in the colon. It supports immune health by supporting tight junctures in the intestinal lining normalizing inflammatory responses in the gastrointestinal tract.
Butyrate prodrug Tributyrin is proven to overcome the pharmacokinetic drawbacks of butyrate supplementation while eliminating bad smell and taste.

Please log-in to view wholesale pricing.

Sign In to View Pricing

Sign In to View Details

Sign In to View Supplement Facts

Cellular Pathways 

The overexpression of GPx causes the blocking of the NF-kB cascade, resulting in the attenuation of the inflammatory response by impairing the expression of NF-kB inflammatory genes.
Butyrate induces maturation and expansion of the colonic regulatory T cells.
PPARy, strongly expressed in the colon, controls the energy production required for microbiome homeostasis through fatty acid oxidation.

Why this matters:

3 days of Abx administered by oral gavage resulted in an early complete loss of bacterial groups. Despite outgrowth of several resistant organisms, cecal contents from abx-treated mice lost the ability to produce SCFAs from inulin and lost HIF expression, both of which are restored by butyrate administration. Butyrate is a potent activator of AMPK in colonic cell lines.
*Kelly, C. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe. 2015; 17(5): 662–671

Clinical Studies

nuButyrate™ Results & Tributyrin (as CoreBiome®)
nuButyrate™ Results
  • Faecalibacterium prausnitzii increased 41% over placebo
  • Anaerostipes increased 67% over placebo
  • Both bacteria are butyrate producers and their benefits are associated with butyrate production (healthy microbiome, immunity, healthy inflammatory response, etc.)

Tributyrin (as CoreBiome®)

  • Has clinically substantiated bioavailability in the colon
  • In a 48-hour study using a gastrointestinal model [and that was repeated in a four-week study], CoreBiome® limited IL6, TNF-alpha and measurements of epithelial function through TEER (transepithelial electrical resistance), suggesting that it may support gut barrier function
  • Is the ONLY SCFA with marketable claims

Synergy with Larazotide, Guttides (BPC-157 + KPV):

Critical components of GI protocols include Guttides (BPC-157 + KPV), Larazotide and low dose pentosan polysulfate.
Larazotide + nuButyrate™
Larazotide protects the gut by improving and repairing tight junctions providing gut permeability protection. Larazotide improves the structure and integrity of the gut while nubutyrate works on creating the optimal environment through immune and inflammation modulation.
The combination of gut health peptides BPC-157 and KPV improve inflammation and mucosal barrier integrity. nuButyrate is commonly used in conjunction to further improve the GI inflammatory state.

References

  1. Mathew OP, Ranganna K, Milton SG. Involvement of the Antioxidant Effect and Anti-inflammatory Response in Butyrate-Inhibited Vascular Smooth Muscle Cell Proliferation. Pharmaceuticals (Basel). 2014 Nov 10;7(11):1008-27. doi: 10.3390/ph7111008. PMID: 25390157; PMCID: PMC4246201.
  2. Pituch A, Walkowiak J, Banaszkiewicz A. Butyric acid in functional constipation. Prz Gastroenterol. 2013;8(5):295-8. doi: 10.5114/pg.2013.38731. Epub 2013 Oct 28. PMID: 24868272; PMCID: PMC4027827.
  3. Jahns F, Wilhelm A, Jablonowski N, Mothes H, Greulich KO, Glei M. Butyrate modulates antioxidant enzyme expression in malignant and non-malignant human colon tissues. Mol Carcinog. 2015 Apr;54(4):249-60. doi: 10.1002/mc.22102. Epub 2014 Mar 28. PMID: 24677319.
  4. Hamer HM, Jonkers DM, Vanhoutvin SA, Troost FJ, Rijkers G, de Bruïne A, Bast A, Venema K, Brummer RJ. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr. 2010 Dec;29(6):738-44. doi: 10.1016/j.clnu.2010.04.002. Epub 2010 May 15. PMID: 20471725.
  5. Hamer HM, Jonkers DM, Bast A, Vanhoutvin SA, Fischer MA, Kodde A, Troost FJ, Venema K, Brummer RJ. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr. 2009 Feb;28(1):88-93. doi: 10.1016/j.clnu.2008.11.002. Epub 2008 Dec 23. PMID: 19108937.
0
  • Item added to cart
0
Your Cart
You're $100.00 away from free shipping.
Your cart is emptyReturn to Shop
    Calculate Shipping
    Shipping options will be updated during checkout.
    Apply Coupon

    Need Help?

    We’re here to help with any questions or concerns you may have!